These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 33358826)
1. Prolonged cultured human hepatocytes as an in vitro experimental system for the evaluation of potency and duration of activity of RNA therapeutics: Demonstration of prolonged duration of gene silencing effects of a GalNAc-conjugated human hypoxanthine phosphoribosyl transferase (HPRT1) siRNA. Yang Q; Humphreys SC; Lade JM; Li AP Biochem Pharmacol; 2021 Jul; 189():114374. PubMed ID: 33358826 [TBL] [Abstract][Full Text] [Related]
2. Messenger RNA Expression of Albumin, Transferrin, Transthyretin, Asialoglycoprotein Receptor, Cytochrome P450 Isoform, Uptake Transporter, and Efflux Transporter Genes as a Function of Culture Duration in Prolonged Cultured Cryopreserved Human Hepatocytes as Collagen-Matrigel Sandwich Cultures: Evidence for Redifferentiation upon Prolonged Culturing. Yang Q; Li AP Drug Metab Dispos; 2021 Sep; 49(9):790-802. PubMed ID: 34135090 [TBL] [Abstract][Full Text] [Related]
3. Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of Ayyar VS; Song D; Zheng S; Carpenter T; Heald DL J Pharmacol Exp Ther; 2021 Nov; 379(2):134-146. PubMed ID: 34413198 [TBL] [Abstract][Full Text] [Related]
4. siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes. Matsuda S; Keiser K; Nair JK; Charisse K; Manoharan RM; Kretschmer P; Peng CG; V Kel'in A; Kandasamy P; Willoughby JL; Liebow A; Querbes W; Yucius K; Nguyen T; Milstein S; Maier MA; Rajeev KG; Manoharan M ACS Chem Biol; 2015 May; 10(5):1181-7. PubMed ID: 25730476 [TBL] [Abstract][Full Text] [Related]
11. The Nonclinical Disposition and Pharmacokinetic/Pharmacodynamic Properties of McDougall R; Ramsden D; Agarwal S; Agarwal S; Aluri K; Arciprete M; Brown C; Castellanos-Rizaldos E; Charisse K; Chong S; Cichocki J; Fitzgerald K; Goel V; Gu Y; Guenther D; Habtemariam B; Jadhav V; Janas M; Jayaraman M; Kurz J; Li J; Liu J; Liu X; Liou S; Maclauchlin C; Maier M; Manoharan M; Nair JK; Robbie G; Schmidt K; Smith P; Theile C; Vaishnaw A; Waldron S; Xu Y; Zhang X; Zlatev I; Wu JT Drug Metab Dispos; 2022 Jun; 50(6):781-797. PubMed ID: 34154993 [TBL] [Abstract][Full Text] [Related]
12. In Vitro Drug-Drug Interaction Evaluation of GalNAc Conjugated siRNAs Against CYP450 Enzymes and Transporters. Ramsden D; Wu JT; Zerler B; Iqbal S; Jiang J; Clausen V; Aluri K; Gu Y; Dennin S; Kim J; Chong S Drug Metab Dispos; 2019 Oct; 47(10):1183-1194. PubMed ID: 31270142 [TBL] [Abstract][Full Text] [Related]
13. Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate. Zimmermann TS; Karsten V; Chan A; Chiesa J; Boyce M; Bettencourt BR; Hutabarat R; Nochur S; Vaishnaw A; Gollob J Mol Ther; 2017 Jan; 25(1):71-78. PubMed ID: 28129130 [TBL] [Abstract][Full Text] [Related]
14. Impact of Serum Proteins on the Uptake and RNAi Activity of GalNAc-Conjugated siRNAs. Agarwal S; Allard R; Darcy J; Chigas S; Gu Y; Nguyen T; Bond S; Chong S; Wu JT; Janas MM Nucleic Acid Ther; 2021 Aug; 31(4):309-315. PubMed ID: 33861634 [TBL] [Abstract][Full Text] [Related]
15. Mutagenesis induced by procarcinogens at the hypoxanthine-guanine phosphoribosyl transferase locus of human fibroblasts cocultured with rat hepatocytes. Michalopoulos G; Strom SC; Kligerman AD; Irons GP; Novicki DL Cancer Res; 1981 May; 41(5):1873-8. PubMed ID: 7214354 [TBL] [Abstract][Full Text] [Related]
16. Effects of culture duration on gene expression of P450 isoforms, uptake and efflux transporters in primary hepatocytes cultured in the absence and presence of interleukin-6: implications for experimental design for the evaluation of downregulatory effects of biotherapeutics. Yang Q; Doshi U; Li N; Li AP Curr Drug Metab; 2012 Sep; 13(7):938-46. PubMed ID: 22475270 [TBL] [Abstract][Full Text] [Related]
17. Lu J; Swearingen E; Hardy M; Collins P; Wu B; Yuan E; Lu D; Li CM; Wang S; Ollmann M Mol Ther Nucleic Acids; 2022 Jun; 28():423-434. PubMed ID: 35505960 [TBL] [Abstract][Full Text] [Related]
18. Novel Cluster and Monomer-Based GalNAc Structures Induce Effective Uptake of siRNAs in Vitro and in Vivo. Sharma VK; Osborn MF; Hassler MR; Echeverria D; Ly S; Ulashchik EA; Martynenko-Makaev YV; Shmanai VV; Zatsepin TS; Khvorova A; Watts JK Bioconjug Chem; 2018 Jul; 29(7):2478-2488. PubMed ID: 29898368 [TBL] [Abstract][Full Text] [Related]
19. Application of improved GalNAc conjugation in development of cost-effective siRNA therapies targeting cardiovascular diseases. Li Q; Yin K; Ma HP; Liu HH; Li S; Luo X; Hu R; Zhang WW; Lv ZS; Niu XL; Gu MH; Li CL; Liu YS; Liu YJ; Li HB; Li N; Li C; Gu WW; Li JJ Mol Ther; 2024 Mar; 32(3):637-645. PubMed ID: 38204163 [TBL] [Abstract][Full Text] [Related]
20. Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates. Brown CR; Gupta S; Qin J; Racie T; He G; Lentini S; Malone R; Yu M; Matsuda S; Shulga-Morskaya S; Nair AV; Theile CS; Schmidt K; Shahraz A; Goel V; Parmar RG; Zlatev I; Schlegel MK; Nair JK; Jayaraman M; Manoharan M; Brown D; Maier MA; Jadhav V Nucleic Acids Res; 2020 Dec; 48(21):11827-11844. PubMed ID: 32808038 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]